Semaglutide vs Hexarelin
Head-to-head comparison of Semaglutide and Hexarelin for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Semaglutide | Hexarelin |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Growth Hormone Secretagogue |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. | Hexarelin binds to and activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus through a triple mechanism: direct stimulation of pituitary somatotroph cells to release stored GH, stimulation of hypothalamic GHRH-releasing neurons, and suppression of somatostatin (the GH-inhibiting hormone). |
| Evidence Rating | A — FDA Approved | C — Phase I–II Clinical Trials |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | Phase II completed. Development discontinued due to tolerance/desensitization concerns. |
| Safety Profile | Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient); Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness | Generally well-tolerated in clinical trials; Transient cortisol and prolactin elevation at higher doses |
| Molecular Weight | ~4113.6 g/mol | ~887 g/mol |
| Half-Life | ~160–168 hours (~7 days) | ~70 minutes |
Overview
Semaglutide and Hexarelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Semaglutide — Mechanism & Evidence
It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Key claims: Causes significant weight loss; Improves blood sugar control; Reduces cardiovascular risk.
Hexarelin — Mechanism & Evidence
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a). It is considered one of the most potent GHRPs available, stimulating greater GH release than GHRH alone. However, it causes relatively rapid receptor desensitization compared to milder GHRPs like ipamorelin, limiting cycle duration to 4-8 weeks. It also has notable cardioprotective properties independent of GH release.
Key claims: Potent GH release; Cardioprotective effects; Improves body composition.
Shared Research Applications
These peptides target different research areas. Semaglutide focuses on Weight Management, Metabolic Health, Cardiovascular, while Hexarelin targets Body Composition, Anti-Aging.
Safety Considerations
Semaglutide: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
Hexarelin: Generally well-tolerated in clinical trials Transient cortisol and prolactin elevation at higher doses Hunger increase (ghrelin receptor activation)
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Semaglutide News: New Meta-Analysis Highlights Weight and Inflammatory Benefits
A recent systematic review and meta-analysis examines the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Early reports suggest meaningful reductions in body weight alongside improvements in inflammatory biomarkers, offering new context for peptide researchers and industry professionals.
Semaglutide News: How Long to Lose 30 Pounds on Semaglutide?
A common question in the semaglutide news cycle is how long it takes to lose 30 pounds on the medication. While individual results vary, clinical trial data and prescribing guidelines offer a general timeline. This article breaks down the expected weight loss trajectory and what factors influence the pace.
Semaglutide News 2026: How to Calculate Peptide Reconstitution
As semaglutide news 2026 continues to generate interest among researchers, understanding how to calculate reconstitution for peptides is essential. This guide covers the math, safety, and practical steps for accurate peptide preparation.